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Background: Genetic variations in calpain-10 and adiponectin gene are known to influence insulin secretion and resistance in type 
2 diabetes mellitus. Recently, several single nucleotide polymorphisms (SNPs) in calpain-10 and adiponectin gene have been report-
ed to be associated with type 2 diabetes and various metabolic derangements. We investigated the associations between specific cal-
pain-10 and adiponectin gene polymorphisms and Korean type 2 diabetes patients.
Methods: Overall, 249 type 2 diabetes patients and 131 non-diabetic control subjects were enrolled in this study. All the subjects 
were genotyped for SNP-43 and -63 of calpain-10 gene and G276T and T45G frequencies of the adiponectin gene. The clinical char-
acteristics and measure of glucose metabolism were compared within these genotypes.
Results: Among calpain-10 polymorphisms, SNP-63 T/T were more frequent in diabetes patients, and single SNP-63 increases the 
susceptibility to type 2 diabetes. However, SNP-43 in calpain-10 and T45G and intron G276T in adiponectin gene were not signifi-
cantly associated with diabetes, insulin resistance, nor insulin secretion.
Conclusion: Variations in calpain-10, SNP-63 seems to increase the susceptibility to type 2 diabetes in Koreans while SNP-43 and 
adiponectin SNP-45, -276 are not associated with impaired glucose metabolism.
Keywords: Calpain 10; Adiponectin; Diabetes mellitus, type 2
INTRODUCTION
There has been a rapid rise in the incidence of type 2 diabetes 
mellitus (DM) in Korea due to a recent economic development 
and industrialization [1]. Insulin resistance (IR) and impaired 
insulin secretion (IIS) are two main pathogenesis of type 2 dia-
betes, and they are related to both the environmental and genetic 
factors. However, very few genes have been identified [1,2]. 
Recently, calpain-10 (CAPN10) gene polymorphism has been 
reported to be associated with the IIS and insulin action as well 
as the development and progression of type 2 diabetes [3]. 
CAPN10 is a calcium activated protein expressed ubiquitously 
in human bodies including heart, skeletal muscles, liver, and 
pancreatic islet cells [4]. It contributes to glucose metabolism 
by regulating insulin secretion from pancreatic β-cells and insu-
lin action at the adipocyte level [4]. Accordingly, it has been re-
ported that CAPN10 gene is a crucial factor for obesity and dia-
betes, and combinations of single nucleotide polymorphisms 
(SNPs) (such as SNP-44, -43, -19, and -63) predominantly lo-
cated in the intron of CAPN10 gene are involved in the develop-
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ment of diabetes [5,6].
Adiponectin is a well-known adipocytokine that is closely re-
lated to IR, obesity, atherosclerosis, and type 2 diabetes [7]. It is 
abundantly expressed in white adipocytes and structurally simi-
lar to collagen VIII and X, complement C1q17-20, and tumor 
necrosis factor-α (TNF-α) [7]. Adiponectin gene is located in 
chromosome 3q27 and composed of 3 exons and 2 introns. It 
has been reported that SNPs, including a silent T to G substitu-
tion (+45T>G) in exon 2 and a G to T substitution (+276G>T) 
in intron 2, are related to low blood adiponectin concentration, 
IR, and type 2 diabetes [8,9].
There are several studies that demonstrated the association 
between genetic variations in the genes coding adiponectin and 
IR, metabolic syndrome as well as the risk of type 2 diabetes in 
Korean population [10,11]. However, not much is known about 
the CAPN10 genetic polymorphism and metabolic derange-
ments in Koreans. Therefore, the present study explored the as-
sociations between CAPN10 and adiponectin gene polymor-
phism and various components of metabolic syndrome, IR and 
secretion, and the incidence of type 2 diabetes in Korean popu-
lation. 
METHODS
Subjects
This study was conducted on 249 Korean type 2 diabetes pa-
tients at Diabetes Center of Gangnam Severance Hospital, Ko-
rea from January 2006 to June 2007. Previously diagnosed dia-
betes patients based on self-reported responses and newly diag-
nosed diabetes patients according to American Diabetes Associ-
ation criteria were all included. Type 1 diabetes patients and 
those who received insulin therapy within 3 years after the diag-
nosis of type 2 diabetes were excluded. The control group was 
composed of 131 non-diabetic patients from Gangnam Sever-
ance Check-up Center. The Institutional Review Board (3-2006-
0005) of Yonsei University College of Medicine approved this 
study protocol, and written informed consent was obtained from 
all subjects.
Anthropometric measurements
Body weight and height were measured in the morning, with 
light clothing without shoes, and body mass index (BMI) was 
calculated by dividing the weight (kg) by the square of the 
height (m2). Waist circumference was measure at the midway 
between the lower margin of the last palpable rib and the top of 
the iliac crest at the end of a normal expiration. Systolic and dia-
stolic blood pressures were measured by an experienced techni-
cian by placing the left arm at heart level after a 5-minute rest. 
Biochemical parameters
Blood samples were taken from all subjects after an overnight 
fast. Standard methods were used for biochemistry. Fasting 
plasma glucose, total cholesterol, high density lipoprotein cho-
lesterol (HDL-C), and triglycerides (TGs) levels were deter-
mined using enzymatic methods with a Hitachi 7600-120 auto-
mated chemistry analyzer (Hitachi, Tokyo, Japan). Low density 
lipoprotein cholesterol (LDL-C) was calculated according to the 
Friedewald formula. Hemoglobin A1c (HbA1c) was determined 
by high performance liquid chromatography (Variant II, Bio-
Rad, Hercules, CA, USA). Fasting serum insulin was deter-
mined by chemiluminescence (RIA kit, Daiichi, Tokyo, Japan), 
and IR was calculated using the homeostasis model assessment 
of insulin resistance (HOMA-IR) index, using following formu-
la: HOMA-IR=glucose (mmol/L)×insulin (μU/mL)/22.5. In-
sulin secretion capacity was calculated using homeostasis model 
assessment of β-cell function (HOMA-β) index using the fol-
lowing formula: HOMA-β=20×insulin (μU/mL)/[glucose 
(mmol/L)–3.5].
Genotyping of polymorphisms in CAPN10 and adiponectin 
gene
CAP10 gene polymorphism
Genomic DNA was isolated from 5 mL of whole blood collect-
ed in ethylenediaminetetraacetic acid (EDTA) tubes. The geno-
type of all patients was classified depending on two CAPN10 
gene polymorphisms (SNP-43, -63), which were analyzed using 
TaqMan (TaqMan fluorogenic 5´ nuclease assay; Applied Bio-
systems, Waltham, MA, USA) and SNaPshot method respec-
tively. Polymerase chain reaction (PCR) reaction solution was 
adjusted to a final volume of 5 µL containing 10 ng of template 
DNA, 0.13 µL of 40X assay mix (Assay ID C_27483762_10), 
and 2.5 µL of TaqMan Universal PCR master mix. Real-time 
PCR was performed in two stages using ABI Prism 7900HT 
Fast Real-Time PCR System (Applied Biosystems, Waltham, 
MA, USA), thus 45 cycles of PCR were done at 95°C for 15 
seconds and at 60°C for 1 minute after an initial denaturation at 
95°C for 10 minutes. PCR analysis was performed using 7900HT 
SDS 2.3 software (Applied Biosystems). Meanwhile, SNaPshot 
assay was employed to analyze SNP-63, and the SNP site was am-
plified using 5´-AGCACCCAGTCCTACCAGTG-3´ (Forward) 
and 5´-CTGGCTGGAGTTTGGAGAAG-3´ (Reverse). PCR 
contained solution was prepared containing 10 ng of 0.5 pM 
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template DNA, 0.5 pM forward/reverse primer, 1l of 10X PCR 
Gold buffer, 250 µM dNTP, 3 mM MgCl2, and 0.25 unit of 
DNA polymerase, and we added distilled water to make a final 
volume of 10 µL. The solution was incubated at 7°C for 7 min-
utes. PCR was carried out with one cycle of 95°C for 10 min-
utes, and 30 cycles of 95°C for 30 seconds, 60°C for 1 minute, 
and 72°C for 1 minute. We added 1 µL of purified PCR products 
to SNaPshot Ready Reaction mixture containing 0.15 pmol ge-
notyping primer (5´-ASAGACGCGGCCCACCCCTC-3´) for 
primer extension reaction, which was conducted in three stages 
with 25 cycles of 96°C for 10 seconds, 50°C for 5 seconds, and 
60°C for 30 seconds. To eliminate excess fluorescent dye termi-
nators, we added 1 unit of shrimp alkaline phosphatase (SAP) to 
the reaction product. The reaction was incubated at 37°C for 1 
hour and at 72°C for 15 minutes. In addition, we added 9 µL of 
Hi-Di formamide to 1 µL of the reaction product, followed by 
incubation at 95°C for 5 minutes. It was then placed on ice for 5 
minutes. Lastly, the reaction was assessed using ABI Prism 
3730xl DNA Analyzer (Applied Biosystems). The final results 
were analyzed using GeneScan analysis software (Applied Bio-
systems).
Adiponectin gene polymorphism
After extracting genomic DNA from the whole blood, SNaP-
shot and TaqMan method were used to analyze the genotypes of 
two adiponectin gene polymorphisms, SNP +45T>G (rs-
2241766) and SNP +276G>T (rs1501299), respectively. The 
overall experiment methods were similar to those of the 
CAPN10. However, the following genotyping assay, namely 
TaqMan assay (Assay ID C_7497299_10), was employed for 
the detection of SNP +276G>T. In SNaPshot assay, the SNP 
+45T>G site was amplified using 5´-AGCACCCAGTCCTAC-
CAGTG-3´ (Forward) and 5´-CTGGCTGGAGTTTGGAGAAG-3´ 
(Reverse), and we used 5´-ASAGACGCGGCCCACCCCTC-3´ as 
a primer.
Statistical analysis
A chi-square test was used to calculate P value for Hardy-Wein-
berg equilibrium in the control group. To analyze the correlation 
between basic information of subjects and diabetes, logistic re-
gression analysis was performed for categorical variables to de-
termine P value, odds ratio (OR), and 95% confidence interval 
(CI) were measured. For continuous variables, mean values of 
the DM patient group were compared to those of the control 
group by a t test. With regard to the correlation between 4-genes 
polymorphisms and diabetes, P value, OR and 95% CI were re-
spectively measured in a diversity of models such as codomi-
nant, additive, dominant, and recessive model. These measure-
ments were adjusted for age, sex, and BMI value. All statistical 
analyses were conducted using SAS version 9.1 (SAS Institute 
Inc., Cary, NC, USA).
RESULTS
Clinical characteristics of study subjects
The genetic polymorphisms were evaluated in 249 patients with 
type 2 diabetes and 131 control subjects. Among 249 diabetes 
patients, there were 158 males and 91 females, and the mean 
age was 56 years. Mean diabetes duration was 7.8 years, and 
mean HbA1c was 8.2%. Two hundred and twenty out of 249 
patients were taking oral hypoglycemic agents and 33 patients 
were on insulin. In the control group, there were 61 males and 
70 females, with the mean age of 54 years. There were no statis-
tically significant differences between the two groups with re-
spect to age and gender. Higher BMI, diastolic pressure, and TG 
and lower HDL-C level was noted in the diabetes group com-
pared to control group. Blood adiponectin level was significant-
ly lower in diabetes group. IR calculated from HOMA-IR and 
Table 1. Clinical Characteristics of the Study Population
Characteristic Diabetic Control P value
No. of subjects (male/female) 249 (158/91) 131 (61/70) NS
Age, yr 56.03±6.73 54.52±6.39 NS
BMI, kg/m2 24.67±3.64 23.73±2.53 0.009
SBP, mm Hg 124.00±10.37 123.39±12.57 NS
DBP, mm Hg 77.57±6.95 75.82±9.29 0.038
FPG, mmol/L 7.75±2.19 5.00±0.33 <0.001
TC, mmol/L 4.84±1.00 5.04±0.96 0.060
TG, mmol/L 1.71±0.95 1.23±0.64 <0.001
LDL-C, mmol/L 2.73±0.85 2.96±0.83 0.010
HDL-C, mmol/L 0.28±0.31 1.40±0.32 0.001
Adiponectin, μg/mL 7.34±4.85 8.47±6.17 0.040
Fasting insulin, μU/L 3.92±4.88 3.34±2.68 NS
HOMA-IR 2.52±4.06 1.35±1.05 <0.001
HOMA-β, % 60.48±65.84 77.42±65.48 0.017
Values are expressed as mean±SD.
NS, not significant; BMI, body mass index; SBP, systolic blood pres-
sure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; TC, 
total cholesterol; TG, triglyceride; LDL-C, low density lipoprotein cho-
lesterol; HDL-C, high density lipoprotein cholesterol; HOMA-IR, ho-
meostasis model assessment of insulin resistance; HOMA-β, homeosta-
sis model assessment of β-cell function.
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insulin secreting capacity calculated from HOMA-β were all 
higher in diabetes group (Table 1).
Associations between SNPs in the adiponectin and 
CAPN10 gene and type 2 diabetes 
The genotype analysis was successfully conducted depending 
on each SNP of adiponectin and CAPN10 except two subjects 
in diabetes group and one subject in control group. For SNP at 
position 276 of adiponectin gene, subjects with TG and GG 
genotypes were less likely to have diabetes compared to those 
with TT genotype. For SNP at position 45 of adiponectin gene, 
those with GT genotype were less likely to have diabetes while 
those with TT were more prone to diabetes compared with sub-
jects with GG genotype (Table 2). For SNP at position 43 of 
CAPN10 gene, subjects with GA were less likely to have diabe-
tes compared with GG genotype while for SNP at position 63, 
those with TT genotypes were more likely to be diabetic com-
pared with CC genotype with a statistical significance (Table 2).
With regard to two SNPs (276G/T, 45T/G) of adiponectin 
gene, whenever T was substituted to G in SNP 276G/T, diabetes 
risk decreased by 91%. In SNP 45T/G, G was dominant, and di-
abetes risk increased by 102% whenever G was substituted to T. 
For two SNPs (-43, -63) of CAPN10 gene, in SNP-43, diabetes 
risk decreased by 80% whenever G was substituted to A while 
Table 2. Association between Adiponectin and CAPN10 Gene Polymorphisms and Type 2 Diabetes
Gene
Co-dominant model
P value
Genotype No. of case (%) No. of control (%) OR (95% CI)
ACDC 276G/T TT 121 (48.6) 60 (45.8) 1.00
TG 102 (41.0) 54 (41.2) 0.91 (0.57–1.45) 0.69
GG 26 (10.4) 17 (13.0) 0.84 (0.41–1.71) 0.63
ACDC 45T/G GG 119 (47.8) 61 (46.6) 1.00
GT 108 (43.4) 60 (45.8) 0.96 (0.61–1.51) 0.86
TT 22 (8.8) 10 (7.6) 1.12 (0.49–2.58) 0.79
CAPN10 43G/A GG 202 (81.1) 101 (77.1) 1.00
GA 44 (17.7) 29 (22.1) 0.76 (0.44–1.31) 0.32
AA 3 (1.2) 1 (0.8) 1.04 (0.10–10.5) 0.97
CAPN10 63C/T CC 132 (53.4) 77 (59.2) 1.00
CT 93 (37.7) 49 (37.7) 1.11 (0.70–1.77) 0.65
TT 22 (8.9) 4 (3.1) 3.38 (1.10–10.4) 0.03
Adjusted for age and gender.
CAPN1, calpain-10; OR, odds ratio; CI, confidence interval; ACDC, adiponectin.
Table 3. Association between Dominant, Recessive Polymorphisms Model and Type 2 Diabetes
Gene
Additive model Dominant model Recessive model
Genotype OR (95% CI) P value Genotype OR (95% CI) P value Genotype OR (95% CI) P value
ACDC 276G/T TT 0.91 (0.66–1.26) 0.58 TT 1.00 TT+TG 1.00
TG+GG 1.00 TG+GG 0.89 (0.58–1.39) 0.61 GG 0.88 (0.45–1.72) 0.71
ACDC 45T/G GG 1.02 (0.72–1.43) 0.93 GG 1.00 GG+GT 1.00
GT+TT 1.00 GT+TT 0.99 (0.64–1.52) 0.94 TT 1.14 (0.51–2.55) 0.74
CAPN10 43G/A GG 0.80 (0.49–1.31) 0.38 GG 1.00 GG+GA 1.00
GA+AA 1.00 GA+AA 0.77 (0.45–1.31) 0.34 AA 1.10 (0.11–11.1) 0.94
CAPN10 63C/T CC 1.39 (0.96–2.00) 0.08 CC 1.00 CC+CT 1.00
CT+TT 1.00 CT+TT 1.28 (0.82–3.01) 0.27 TT 3.23 (1.06–9.79) 0.04
Adjusted for age and gender.
OR, odds ratio; CI, confidence interval; ACDC, adiponectin; CAPN10, calpain-10.
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in SNP-63, diabetes risk increased by 139% whenever C was 
substituted to T. However, these results were not statistically 
significant (Table 3). 
We analyzed the prevalence of diabetes with regard to the 
dominant model of each gene. When assuming the prevalence 
of diabetes in TT genotype at SNP 276G/T of adiponectin gene 
to be 100%, that of TG+GG genotype was 89%. When assum-
ing the diabetes prevalence with GG genotype in SNP 45T/G to 
be 100%, that of GT+TT genotype was 99%. In SNP-43 of 
CAPN10, when assuming the prevalence of diabetes in GG 
genotype to be 100%, that of the remaining GA+AA genotype 
was significantly low with 77%. In SNP-63, assuming that the 
prevalence of CC genotype is 100%, that of the remaining 
CT+TT genotype was 128% but not statistically significant (Ta-
ble 3). In terms of recessive model of each gene, when assum-
ing the prevalence of TT+TG genotype in SNP 276G/T of adi-
ponectin gene to be 100%, that of GG genotype was 88%. 
When assuming the prevalence of GG+GT genotype in SNP 
45T/G to be 100%, that of TT genotype was 114%. In SNP-43 
of CAPN10, when the prevalence of GG+GA genotype is 
100%, that of the remaining AA genotype was high as 110% but 
not statistically significant. On the other hand, in SNP-63, when 
the prevalence of CC+CT genotype is 100%, that of the remain-
ing TT was significantly high as 323% (OR, 3.23; 95% CI, 1.06 
to 9.79) (Table 3). 
We applied dominant and recessive models to each gene 
polymorphism and analyzed the correlation between the models 
and each parameter. With regard to the recessive model with 
two substituents, fasting blood glucose levels in TT genotype of 
SNP-63 were 163.77±49.28 and significantly higher than those 
in TC+CC genotype (138.91±38.19). In SNP 276G/T, blood 
adiponectin levels in TT genotype were 5.08±2.64 and signifi-
cantly lower than those in TG+GG genotype (7.57±4.97). For 
the dominant model, in SNP-43, fasting blood glucose levels in 
GG and GT+TT genotype were 143.70±42.19 and 130.33±
25.44 respectively and the increased levels in GG genotype 
were meaningful. In SNP-63, blood insulin levels in CC geno-
type (3.27±2.83) were lower than those in CT+TT genotype 
(4.65±6.43). Similarly, HOMA-IR in CC genotype (20.34±
23.07) was significantly lower than that in CT+TT genotype 
(30.77±53.73).
DISCUSSION
It has been known that several causes, mainly obesity, environ-
mental factors and inherited metabolic disease, are engaged in 
type 2 diabetes [10]. Among diverse metabolic disorders, in-
creased IR and IIS are considered the most critical pathogenetic 
factors in the development type 2 diabetes [6,7]. 
Prior cross-sectional and follow-up studies revealed that IR 
precedes IIS. That is, in early stages of diabetes, normal glucose 
tolerance is detected due to a complementary rise of insulin se-
cretion to overcome IR. However, with a progressive decrease 
in insulin secretory capacity hyperglycemia is induced and fi-
nally heads to type 2 diabetes [9]. IR is caused by impaired in-
sulin signaling in target organs and specifically associated with 
obesity. Indeed, it is considered that adipocytes are mediated by 
many proteins related to IR such as TNF-α, leptin, free fatty 
acid, and angiotensinogen [12,13]. Adiponectin is also related to 
cardiovascular disease and its blood concentration declined in 
patients with obesity and type 2 DM [8,9]. Accordingly, adipo-
nectin increases insulin sensitivity and shows an anti-athero-
sclerotic effect applied directly to blood vessels. Moreover, adi-
ponectin administration reduces blood glucose levels and im-
proves lipid metabolism. Adiponectin gene is located in chro-
mosome 3q27 and consists of three exons and two introns. It 
has been reported that SNPs such as a silent T to G substitution 
(+45T>G) in exon 2 and a G to T substitution (+276G>T) in 
intron 2 are related to reduced blood adiponectin levels, IR and 
type 2 DM [14].
CAPN10 gene has been recently reported as a critical factor 
of IIS. It is located in chromosome 2q37 and expressed to gly-
coproteins with 672 amino acids, which belong to the calpain 
family of calcium-dependent intracellular cysteine proteases 
[4,15]. This protein is a neutral protease activated by calcium 
ions and resides in the cytosol in an inactivated form. However, 
with increased intracellular calcium levels, it is transported to 
the cell membrane and then activated there. CAPN10 mRNA is 
expressed in various tissues in human body including pancreatic 
islets, muscle and liver, which are three most important tissues 
controlling glucose homeostasis. Thus, although its exact mech-
anism is not known, it is suggested that CAPN10 is involved in 
insulin secretion of pancreatic β-cells possibly by regulating 
exocytosis in pancreatic β-cells [5,6,16] as well as insulin action 
and hepatic glucose production [17]. Moreover, 14 calpain iso-
enzymes and their encoding genes have been identified up to 
now, and the CAPN10 gene among them is currently highlight-
ed in terms of obesity and diabetes. More importantly, it has 
been revealed that combinations of SNPs (SNP-44, -43, -19, 
and -63) located mainly in the intron of CAPN10 gene are asso-
ciated with the prevalence of diabetes [15,18,19]. In the present 
study, based on prior studies that investigated the relationship 
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between combinations of SNPs (SNP-43, -19, and -63) and dia-
betes in Koreans, we conducted genetic analysis for SNP-43 
and -63, as well as for SNP-45 and -276 of adiponectin gene to 
elucidate whether these SNPs increase diabetes as well.
In this study, subjects with TT genotype in SNP-63 of 
CAPN10 gene were significantly more likely to have diabetes 
but other SNPs were not associated with diabetes. Previous 
studies show conflicting results regarding CAPN10 polymor-
phism and the risk of type 2 DM. For example, a case-control 
study conducted with Tunisians showed that only certain haplo-
type combinations of SNPs (SNP-43, -19, and -63) and not a 
single SNP was related to diabetes [20]. However, other studies 
showed a single genotype to be associated with type 2 diabetes. 
A study conducted in British/Irish population reported that a 
single genotype in SNP-44 of CAPN10 was related to type 2 di-
abetes but not SNP-43, -19, and -63 [4,17]. Also, studies in 
Mexican and Indian populations showed diverse associations 
[21,22], suggesting an ethnic difference in the association be-
tween CAPN10 polymorphism and diabetes among different 
populations [23].
Meanwhile, plasma levels of adiponectin secreted in adipo-
cytes were significantly higher in control group compared to di-
abetes group. Adiponectin increases insulin sensitivity by aug-
menting fatty acid oxidation in muscles and reducing gluconeo-
genesis in the liver [17,22]. These adiponectin effects are known 
to be attributed to activation of 5`adenosine monophosphate-ac-
tivated protein activated protein kinase which is a key enzyme 
involved in fatty acid oxidation and glucose intake in muscles 
and gluconeogenesis in the liver [24]. In addition, it was report-
ed that SNPs of adiponectin gene, including a T to G substitu-
tion (T45G) in exon 2 and a G to T substitution (G276T) in in-
tron 2, were related to the components of type 2 diabetes and IR 
syndrome, and this relation was mediated by reduced plasma 
levels of adiponectin [25]. In this context, on the assumption 
that adiponectin gene polymorphisms, or furthermore certain 
genes, may be associated with metabolic parameters, we con-
ducted a genetic analysis expecting the synergistic effect of the 
genes and the CAPN10 gene on metabolic parameters [26]. 
However, the relation between certain genetic variants in both 
SNP-45 and -276 of adiponectin gene and metabolic disorders 
was not confirmed. On the other hand, given that results varied 
depending on race in previous studies similarly to those per-
formed in Korea, our results correspond partially to some re-
ports that both SNP-45 and -276 are less related to metabolic 
disorders.
In the present study, although exploring the correlation be-
tween CAPN10, as well as adiponectin and glucose metabolism, 
and expecting the synergic effect between the key SNP geno-
type combinations, we could not demonstrate the synergic effect 
because no SNPs other than SNP-63, showed statistically sig-
nificant correlations with type 2 diabetes or metabolic parame-
ters as a single genotype [27-29]. When parameters were com-
pared according to each gene polymorphism limited only in the 
diabetes group, there were a great number of meaningful results. 
In 45T/G polymorphism of adiponectin gene, significant differ-
ences were not found. On the contrary, for 276G/T polymor-
phism, adiponectin was significantly reduced in the TT geno-
type group that G was substituted to T. This result is in accor-
dance with the findings of prior studies that a G to T substitution 
of adiponectin gene led to reduced adiponectin and thus was 
closely connected to metabolic disorders [30,31]. For SNP-43 
of CAPN10 gene, fasting blood glucose levels were higher in 
GG genotype, compared to GA+GG, genotype, and this result 
corresponds to that of a prior study that GG genotype contrib-
utes to the development of type 2 diabetes by increasing IR [32]. 
For SNP-63, there was significant difference between the diabe-
tes and control group. Low fasting blood insulin levels and 
HOMA-IR were observed in CC genotype even in the group 
limited diabetes patients. Accordingly, these results suggested 
that a C to T substitution in the CC dominant type increased 
blood insulin levels and IR, thereby it was more closely associ-
ated with type 2 diabetes.
Our study has several limitations. First, many diabetes pa-
tients were taking lipid lowering or antihypertensive drug as 
well as oral hypoglycemic drugs. These drugs could have af-
fected insulin secretory function as well as IR and blood adipo-
nectin level [30,31]. Also, this has led to control subjects having 
higher LDL-C compared with diabetes group. Secondly, the 
family history of diabetes was not assessed in this study. It very 
important especially among the control subjects in terms of a 
genetic predisposition to the future development of diabetes. 
Moreover, the study was conducted with relatively small num-
ber of subjects. A further larger scale study should be conducted 
to confirm the relationship between adiponectin and CAPN10 
gene polymorphism and type 2 diabetes in Korea as well as to 
elucidate the underlying mechanism explaining the effect of ge-
netic polymorphism on diabetes and metabolic derangements.
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